Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $16.55M rose 42.2% year over year, ahead of the +31.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $1.08M (-97.8%) for the fiscal year ending Dec 2026, a slowdown from the +4.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$16.55M+2.6% QoQ
Last fiscal yearDec 2025
$47.91M+4.7% YoY
LTMSep 2026
$60.45M+31.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.2%-100.0%-142.2 pp
1 year+4.7%-97.8%-102.4 pp
3-year CAGR+18.9%-63.0%-81.8 pp
5-year CAGR+115.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
47.91M USD
Year-over-year change
+4.7%
4-year CAGR
+15.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.0% is the 5th highest of 9, against a peer median of +34.4%.
  • Selling, general & admin amounts to 66.8% of revenue for SYRE, versus a peer median of 269.8%.
SYRE Competitors
Selling, General & Admin for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$356.28M USD+23.3%+63.9%83.3%
ABVXAbivax S.A.FY2025€72.87M EUR+87.3%+113.4%—
ANABAnaptysBio, Inc.LTM Mar 2026$62.81M USD+42.2%+11.5%27.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$60.45M USD+31.0%+18.9%66.8%
UPBUpstream Bio, Inc.LTM Mar 2026$27.71M USD+38.6%+59.9%834.2%
IMUXImmunic, Inc.LTM Mar 2026$23.53M USD+30.1%+11.7%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€9.82M EUR+63.8%——
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —+34.4%+11.7%269.8%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.